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Abstract
EFSA asked the Panel on Dietetic Products, Nutrition and Allergies (NDA) to update the scientiﬁc and
technical guidance for the preparation and presentation of an application for authorisation of a health
claim published in 2011. Since then, the NDA Panel has gained considerable experience in the
evaluation of health claims. Lessons learnt from these experiences have been translated into a new
General scientiﬁc guidance for stakeholders on health claim applications (published in January 2016).
In this context, it is noted the need to adapt the existing guidance to the new scientiﬁc and technical
developments in this area. This guidance document presents a common format for the organisation of
information for the preparation of a well-structured application for authorisation of health claims which
fall under Articles 13(5), 14 and 19 of Regulation (EC) No 1924/2006. This guidance outlines the
information and scientiﬁc data which must be included in the application, the hierarchy of different
types of data and study designs, and the key issues which should be addressed in the application to
substantiate the health claim.
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Summary
The European Food Safety Authority (EFSA) asked the Panel on Dietetic Products, Nutrition and
Allergies (NDA) to update the scientiﬁc and technical guidance for the preparation and presentation of
an application for authorisation of a health claim, which was published in 2007 and subsequently
revised in 2011 to include purely administrative nature modiﬁcations.
Since then, the NDA Panel has gained considerable experience in the evaluation of health claims,
and has also increased interactions and exchange of views with stakeholders. Lessons learnt from
these experiences have been translated into a General scientiﬁc guidance for stakeholders on health
claim applications (published in January 2016). In this context, it is noted the need to adapt the
existing guidance for the preparation and presentation of an application for authorisation of a health
claim to the new scientiﬁc and technical developments in this area.
The updated guidance has been aligned with the General scientiﬁc guidance for stakeholders on
health claim applications and adapted to include claims that are based on the essentiality of nutrients.
It has also been restructured concerning Parts 1–6 including the Appendices to clearly outline the
information to be provided.
This guidance applies to health claims related to the consumption of a food category, a food or its
constituents (including a nutrient or other substance, or a ﬁxed combination of constituents); hereafter
referred to as food/constituent.
The guidance presents a common format for the organisation of information for the preparation of
a well-structured application for authorisation of health claims, which fall under Articles 13(5), 14 and
19 of Regulation (EC) No 1924/2006. Adhesion to the guidance will help the NDA Panel to deliver its
scientiﬁc opinion in an effective way and avoid delay in the evaluation process.
It is important to consider whether or not the health claim proposed is based on the essentiality of
nutrients. Data requirements for claims based on the essentiality of nutrients differ compared to other
claims, e.g. for the characterisation of the food/constituent, for the characterisation of the claimed
effect, for the scientiﬁc substantiation of the claim and for establishing conditions of use.
The application must contain:
• A proposal for the wording of the health claim and the speciﬁc conditions of use.
• Information on the characteristics of the food/constituent for which the claim is made.
• Information to allow characterisation of the claimed effect. For function claims, the (speciﬁc)
function of the body that is the target of the claim should be speciﬁed; for reduction of disease
risk claims, both the risk factor and the disease to which the risk factor relates should be
identiﬁed. A rationale that the proposed changes in the function or the risk factor for disease
are beneﬁcial physiological effects for the target population for which the claim is intended
should be provided, together with the outcome variable(s) and methods of measurement
which could be used to assess such changes in in vivo in humans.
• All pertinent scientiﬁc data (published and unpublished, data in favour and not in favour) which
form the basis for substantiation of the health claim.
For claims based on the essentiality of nutrients, data on the essential mechanistic role in a
metabolic function and/or the speciﬁc clinical signs and symptoms of deﬁciency should be
provided. The procedure followed to identify the evidence on the essentiality of the nutrients
should be depicted.
For claims other than those based on the essentiality of nutrients, data from studies in humans
addressing the relationship between the consumption of the food/constituent and the claimed
effect are required for substantiation. Data from studies in animals or other model systems
alone cannot substitute for human data, but may be included only as supporting evidence, for
example to provide evidence on the biological plausibility of the speciﬁc claim, including
evidence on the mechanisms by which the food/constituent could exert the claimed effect. A
comprehensive review of published human studies addressing the speciﬁc relationship between
the food/constituent and the claimed effect is required. This review for the identiﬁcation of
pertinent studies to the health claim should be performed in a systematic and transparent
manner in order to demonstrate that the application adequately reﬂects the balance of all the
evidence available. The procedure followed to identify unpublished human studies that are
considered as pertinent to the health claim should be depicted.
• Data provided to substantiate a health claim should be of high quality with respect to the
methodology and reporting. In cases where any of the required data are not relevant for a
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particular application, reasons/justiﬁcation must be given for the absence of such data in the
application.
As speciﬁed in the Regulation, health claims should be substantiated by taking into account the
totality of the available scientiﬁc data and by weighing the evidence, subject to the speciﬁc conditions
of use. In particular, the evidence should demonstrate the extent to which:
i) the food/constituent is deﬁned and characterised;
ii) the claimed effect is based on the essentiality of a nutrient, OR
the claimed effect is deﬁned and is a beneﬁcial physiological effect for the target population,
and can be measured in vivo in humans;
iii) the food/constituent is required for normal human body function(s) (i.e. it has an essential
mechanistic role in a metabolic function and/or it has the ability to reverse clinical signs and
symptoms of its deﬁciency), it cannot be synthesised by the body, or cannot be synthesised in
amounts which are adequate to maintain the normal body function that is the subject of the
health claim, it must be obtained from a dietary source, OR
a cause and effect relationship is established between the consumption of the
food/constituent and the claimed effect in humans (for the target group under the proposed
conditions of use), by considering the strength, consistency, speciﬁcity, dose–response, and
biological plausibility of the relationship;
iv) the quantity of the food/constituent and pattern of consumption required to obtain the
claimed effect could reasonably be achieved as part of a balanced diet.
The guidance was subject to public consultation (from 18 July to 12 September 2016). This
guidance supersedes the scientiﬁc and technical guidance for the preparation and presentation of an
application for authorisation of a health claim published in 2011 (revision 1). It is intended that the
guidance will be further updated as appropriate in the light of experience gained from the evaluation
of health claims.
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Background and Terms of Reference as provided by EFSA
Background
Regulation (EC) No 1924/20061 harmonises the provisions related to nutrition and health claims
and establishes rules governing the Community authorisation of health claims made on foods.
According to the Regulation, health claims should be only authorised for use in the Community after a
scientiﬁc assessment of the highest possible standard to be carried out by the European Food Safety
Authority (EFSA).
Owing to the scientiﬁc and technical complexity of health claims, the EFSA Panel on Dietetic
products, Nutrition and Allergies (NDA Panel) has placed considerable efforts on developing scientiﬁc
criteria for the substantiation of health claims, and has published guidance on the scientiﬁc
substantiation of health claims since 2007.2
In the last years, the NDA Panel has gained considerable experience in the evaluation of health
claim applications. Interactions and exchange of views with stakeholders have also increased
considerably, both through a technical meeting3 and through public consultations on guidance
documents. The NDA Panel has translated the lessons learnt from these experiences into a revised
General scientiﬁc guidance for stakeholders on health claim applications,4 which was recently published
and represents a step forward in assisting applicants to compile their applications for health claims
authorisation. In this context, it is noted the need to adapt the existing scientiﬁc and technical
guidance for stakeholders5 to the new scientiﬁc and technical developments in this area.
To this end, the NDA Panel is asked to update the scientiﬁc and technical guidance for the
preparation and presentation of an application for authorisation of a health claim.6
Terms of Reference
The NDA Panel is requested by EFSA to update the scientiﬁc and technical guidance for the
preparation and presentation of an application for authorisation of a health claim.
The guidance document shall clarify and address the scientiﬁc and technical developments in this
area, taking into account the experience gained by the NDA Panel with the evaluation of health claims
and the comments received from stakeholders in technical meetings and public consultations.
The draft guidance shall be released for public consultation prior to ﬁnalisation.
The draft guidance shall be revised taking into account the comments received during the public
consultation before the adoption by the NDA Panel. A technical report on the outcome of the public
consultation shall be published.
Introduction
1. Scope
The guidance presented in this document is for preparing and presenting applications for
authorisation of health claims which fall under Article 14 of the Regulation, i.e. reduction of disease
risk claims and claims referring to children’s development and health.
The guidance is also applicable to applications for authorisation of health claims which fall under
Article 13(5) of the Regulation, i.e. which are based on newly developed scientiﬁc evidence and/or
which include a request for the protection of proprietary data.
Applications for the modiﬁcation of existing authorisations of health claims in accordance with
Article 19 of the Regulation shall also be presented, as appropriate, in the format outlined in this
document.
1 Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and health
claims made on foods. OJ L 404, 30.12.2006, p. 9–25.
2 http://www.efsa.europa.eu/en/nda/ndaclaims.htm
3 http://www.efsa.europa.eu/it/supporting/pub/569e
4 http://www.efsa.europa.eu/it/efsajournal/pub/4367
5 Scientiﬁc and technical guidance for the preparation and presentation of an application for authorisation of a health claim.
http://www.efsa.europa.eu/en/efsajournal/pub/2170
6 http://www.efsa.europa.eu/en/efsajournal/pub/2170
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2. Objectives
Without prejudice to Commission Regulation (EC) No 353/2008, the guidance presented in this
document is intended to assist applicants in the preparation and presentation of well-structured
applications for authorisation of health claims.
It presents a common format for the organisation of the information to be provided and outlines:
• the information and scientiﬁc data which must be included in the application, i.e. for health
claims which are based on the essentiality of nutrients and for other health claims;
• the hierarchy of different types of data and study designs, reﬂecting the relative strength of
evidence which may be obtained from different types of studies;
• the key issues which should be addressed in the application to substantiate the health claim.
This guidance supersedes the scientiﬁc and technical guidance for the preparation and presentation
of an application for authorisation of a health claim published in 2011 (revision 1).
It is intended that the guidance will be kept under review, and will be further updated as
appropriate in the light of experience gained from the evaluation of health claims.
General principles
This document should be read in conjunction with Regulation on Nutrition and Health Claims made
on foods,7 the Guidance on the implementation of Regulation (EC) No 1924/2006 (Standing
Committee on the Food Chain and Animal Health, 2007), Commission Regulation (EC) No 353/20088,
the Commission Implementing Decision (2013/63/EU) of 24 January 2013,9 and future guidelines and
regulations, as applicable.
In particular, it should be read together with the general scientific guidance for stakeholders on
health claim applications (EFSA NDA Panel, 2016), hereafter ‘general guidance’, for a better
understanding of the principles and the approach used by the NDA Panel for the scientiﬁc evaluation
of health claims. Cross-reference to relevant sections of the afore-mentioned ‘general guidance’ will be
given throughout this guidance, where applicable.
1) This guidance applies to health claims related to the consumption of a food category, a food
or its constituents (including a nutrient or other substance, or a ﬁxed combination of
constituents); hereafter referred to as food/constituent. A ﬁxed combination of
constituents means two or more nutrients, and/or other substances which are all required in
order to obtain the claimed effect, ideally in speciﬁed amounts.
2) In the context of this guidance document:
– The term application means a stand-alone dossier containing the information and the
scientiﬁc data submitted for the authorisation of a health claim.
– A disease/disorder means a pathological process, acute or chronic, inherited or
acquired, of known or unknown origin, having a characteristic set of signs and symptoms
which are used for its diagnosis. The diagnosis of diseases/disorders relies on widely
accepted, well-deﬁned criteria (i.e. the criteria used for diagnosis are widely accepted by
the medical community and can be veriﬁed by a physician). In this guidance document,
the term disease is used to include diseases and disorders, which for the purpose of this
guidance are considered as synonymous and have the same meaning.
– The totality of the evidence describes all the studies (e.g. in humans, in animals,
in vitro) which are taken into consideration to conclude on the substantiation of a claim
(including studies in favour and not in favour of the claim).
7 Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and health
claims made on foods. OJ L 404, 30.12.2006, p. 9–25. Available at http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=
CONSLEG:2006R1924:20100302:EN:PDF
8 Commission Regulation (EC) No 353/2008 of 18 April 2008 establishing implementing rules for applications for authorisation of
health claims as provided for in Article 15 of Regulation (EC) No 1924/2006 of the European Parliament and of the Council
(Text with EEA relevance) (OJ L 109, 19.4.2008, p. 11): http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CONSLEG:
2008R0353:20091221:EN:PDF
9 Commission Implementing Decision of 24 January 2013 adopting guidelines for the implementation of speciﬁc conditions for
health claims laid down in Article 10 of Regulation (EC) No 1924/2006 of the European Parliament and of the Council. OJ L 22,
25.1.2013, p. 25–28. Available at http://eur-lex.europa.eu/legal-content/EN/ALL/?uri=CELEX:32013D0063
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– Efﬁcacy study refers to an intervention study (in humans, in animals) which investigates
the relationship between the food/constituent and the claimed effect.
– Pertinent study means a study from which scientiﬁc conclusions that are relevant to the
substantiation of a claim (e.g. efﬁcacy studies, bioavailability studies, studies on the
mechanism(s) by which a food could exert the claimed effect) can be drawn.
– Supportive evidence refers to studies/data which, on their own, are not sufﬁcient for
the scientiﬁc substantiation of a claim and that may be part of the totality of the evidence
only if pertinent human studies showing an effect of the food/constituent are available.
– The target population is the population group(s) for which health claims are intended
(e.g. the general healthy population or speciﬁc subgroup(s) thereof).
– The study group denotes individuals recruited for human studies which are submitted for
the scientiﬁc substantiation of a claim.
– A suitable study group means a study group which is representative of the target
population for the claim or a study group from which extrapolation of the results to the
target population is biologically appropriate.
3) This guidance presents a common format for the organisation of the information in order to
assist applicants in the preparation of well-structured applications. Adherence to the guidance
will facilitate easy access to information and scientiﬁc data in applications to help the NDA
Panel to deliver its scientiﬁc opinion in an effective way and avoid delay in the evaluation
process.
4) It is the duty of the applicant to provide all the available scientiﬁc data (including data in
favour and not in favour, published and unpublished) which are pertinent to the health claim
in order to demonstrate that the health claim is substantiated by the totality of the scientiﬁc
data. In its evaluation, the NDA Panel may use data which are not included in the application
if they are considered pertinent to the claim. However, the NDA Panel should not be required
to undertake any additional literature reviews, to assemble or process data in order to
evaluate the application. As such, the application should be comprehensive and complete.
Each application will be considered on a case by case basis.
5) One application should be prepared for each individual health claim; this means that only one
relationship between a food/constituent and a single claimed effect can be the object of each
application. However, multiple formulations of a food/constituent10 can be proposed by the
applicant in the same application as candidates to bear the health claim, provided that the
scientiﬁc evidence is valid for all proposed formulations of a food/constituent bearing the
health claim.
6) In cases where some of the data mentioned in this guidance do not apply to a particular
application, reasons/justiﬁcation must be given for the absence of such data in the
application.
7) It is important to consider whether or not the claimed effect proposed is based on the
essentiality of nutrients. Data requirements for claims based on the essentiality of nutrients
differ compared to other claims, e.g. for the characterisation of the food/constituent, for the
characterisation of the claimed effect, for the scientiﬁc substantiation of the claim and for
establishing conditions of use (EFSA NDA Panel, 2016).
8) The application must include a proposal for the wording of the health claim and the speciﬁc
conditions of use. The target population for the health claim, the quantity of the
food/constituent and pattern of consumption required to obtain the claimed effect, and
whether this quantity could reasonably be consumed as part of a balanced diet should be
speciﬁed. Where appropriate, the following should be provided, with a rationale: a statement
addressed to persons who should avoid using the food/constituent for which the health claim
is made; a warning for any food/constituent that is likely to present a health risk if consumed
in excess; any other restrictions of use; directions for preparation and/or use.
9) The application must contain information on the characteristics of the food/constituent for
which the claim is made. Such characteristics may depend not only on the nature of the
food/constituent, but also on the claimed effect. Where applicable, this information should
contain aspects such as the composition, physical and chemical characteristics, manufacturing
process, and stability, in order to show consistency in the ﬁnal product for those
10 For example, a food product available in different ﬂavours (e.g. vanilla, chocolate) or formats (e.g. tablets, powder, liquid).
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characteristics considered to inﬂuence the claimed effect. Measurements should be performed
in a competent facility which can certify the data.11 Whenever a quality control system is in
place for performance/control/documentation (e.g. good manufacturing practice (GMP), good
laboratory practice (GLP), applicable ISO standard), the particular system should be indicated.
10) The application must also contain information to allow characterisation of the claimed effect.
Such information may depend on the type of claim. For function claims, the (speciﬁc) function
of the body that is the target of the claim should be speciﬁed; for reduction of disease risk
claims, both the risk factor and the disease should be identiﬁed. A rationale that the proposed
changes in the function or the risk factor for disease are beneﬁcial physiological effects for the
target population for which the claim is intended should be provided, together with the
outcome variables and methods of measurement which could be used to assess such changes
in in vivo in humans.
11) For claims based on the essentiality of nutrients,12 data (e.g. depletion–repletion studies in
human, case reports) on the essential mechanistic role in a metabolic function and/or the
speciﬁc clinical signs and symptoms of deﬁciency should be provided. The procedure followed
to identify the evidence on the essentiality of the nutrients should be depicted.
12) For claims other than those based on the essentiality of nutrients,13 data from studies in
humans addressing the relationship between the consumption of the food/constituent and the
claimed effect are required for substantiation. Because of the scientiﬁc uncertainties in
extrapolating non-human data to humans, data from studies in animals or other model
systems alone cannot substitute for human data, but may be included only as supporting
evidence, for example to provide evidence on the biological plausibility of the speciﬁc claim,
including evidence on the mechanisms by which the food/constituent could exert the claimed
effect.
A comprehensive review of published human studies addressing the speciﬁc relationship
between the food/constituent and the claimed effect is required. This review for the
identiﬁcation of pertinent studies to the health claim should be performed in a systematic and
transparent manner in order to demonstrate that the application adequately reﬂects the
balance of all the evidence available. The procedure followed to identify unpublished pertinent
human studies to the health claim should be depicted.
Data from intervention and observational studies in humans should be organised according to
a hierarchy of study designs, and should reﬂect the relative strength of evidence which may
be obtained from different types of studies. Well-designed and conducted randomised
controlled trials (i.e. at low risk of bias) investigating the effect of a food/constituent which
complies with the speciﬁcations of the food/constituent for which the claim is proposed on
appropriate outcome variables for the claimed effect, in a suitable study group, and under the
conditions of use proposed for the claim are at the top of the hierarchy which informs
decisions on substantiation.
13) Data provided to substantiate a health claim should be of high quality with respect to the
methodology and reporting. Whenever a quality control system has been used/reported in the
conduct of the studies (e.g. GLP, good clinical practice (GCP), as relevant), the particular
system should be indicated.
The quality of reporting should be sufﬁcient to allow a full scientiﬁc assessment of the studies
by the NDA Panel. Study reports for human efﬁcacy studies (unpublished and/or proprietary)
not complying with the requirements outlined in Appendix C may not allow a scientiﬁc
evaluation of the study by the NDA Panel. For transparency reasons, the registration of
protocols and publication of results of the human studies submitted for the substantiation of
health claims are highly recommended.14 Journal abstracts and articles published in
newspapers, magazines, newsletters or hand-outs, books or chapters of books for consumers
or the general public should not be cited.
11 E.g. Information on the accreditation of the involved facility should be provided.
12 See also section 6.1 of the ‘general guidance’ (EFSA NDA Panel, 2016).
13 See also sections 6.2, 7.3 and 7.4 of the ‘general guidance’ (EFSA NDA Panel, 2016).
14 http://onlinelibrary.wiley.com/doi/10.2903/sp.efsa.2014.EN-569/pdf
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14) As speciﬁed in the Regulation, health claims should be substantiated by taking into account
the totality of the available scientiﬁc data and by weighing the evidence, subject to the
speciﬁc conditions of use. In particular, the evidence should demonstrate the extent to which:
i) the food/constituent is deﬁned and characterised;
ii) the claimed effect is based on the essentiality of a nutrient, OR
the claimed effect is deﬁned and is a beneﬁcial physiological effect for the target
population, and can be measured in vivo in humans;
iii) the food/constituent is required for normal human body function(s) (i.e. it has an essential
mechanistic role in a metabolic function and/or it has the ability to reverse clinical signs
and symptoms of its deﬁciency), it cannot be synthesised by the body, or cannot be
synthesised in amounts which are adequate to maintain the normal body function that is
the subject of the health claim, it must be obtained from a dietary source, OR
a cause and effect relationship is established between the consumption of the
food/constituent and the claimed effect in humans (for the target group under the
proposed conditions of use), by considering the strength, consistency,15 speciﬁcity, dose–
response, and biological plausibility of the relationship.
iv) the quantity of the food/constituent and pattern of consumption required to obtain the
claimed effect could reasonably be achieved as part of a balanced diet.16
15) The entire application in itself cannot be claimed as conﬁdential. Speciﬁc parts, sections,
words, graphs or data sets considered as conﬁdential by the applicant should be kept to a
minimum and clearly identiﬁed. The applicant is required to provide detailed and veriﬁable
justiﬁcation for every part of the dossier claimed as conﬁdential.17
16) As deﬁned in the Regulation, EFSA will make public the summary of the application when
received and as provided by the applicant. EFSA will also make public, once adopted, its
scientiﬁc opinion on the data and information included in the application, excluding the
information considered as conﬁdential.
Organisation and content of the application
The following information should be provided in the application, and the structure should follow a
common format, i.e. order and numbering system (particularly for the Parts, their main heading and
ﬁrst and second subheadings). Data provided in the application should be organised into six Parts.
• Part 1 contains the speciﬁc requirements for the administrative and technical data, such as
information related to the applicant and the nature of the application (including regulatory
status of the health claim), health claim particulars, the application form and the summary of
the application.
• Part 2 contains information for the characterisation of the food/constituent that is the target
for the claim.
• Part 3 contains information for the characterisation of the claimed effect.
• Part 4 contains all pertinent scientiﬁc data (published and unpublished, data in favour and not
in favour) which form the basis for substantiation of the health claim.
• Part 5 comprises an overall summary of the pertinent scientiﬁc data.
• Part 6 comprises the glossary or abbreviation of terms quoted throughout the different Parts,
full reprints of pertinent publications, full study protocols and study reports of unpublished
pertinent data, and scientiﬁc opinions of regulatory bodies outside the European Union (EU).
Where some of the data described in this guidance do not apply to a particular application,
reasons/justiﬁcation must be given for the absence of such data in the application.
If a study appears under different Parts, cross-references should be given.
15 Consistent results obtained from studies by different research groups and/or in different settings strengthen the evidence.
16 For claims based on the essentiality of nutrients, conditions of use are set on the basis that any signiﬁcant amount of the
essential nutrient in the diet will contribute to the claimed effect (e.g. conditions of use can be linked to nutrition claims). See
also section 7.9 of the ‘general guidance’ (EFSA NDA Panel, 2016).
17 More information about how EFSA handles conﬁdential data can be found in Annex A, section A.4. of the General scientiﬁc
guidance for stakeholders on health claim applications, available at: http://www.efsa.europa.eu/it/efsajournal/pub/4367
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1. Part 1: Administrative and technical data
1.1. Comprehensive table of contents of the application
1.2. Applicant
1.2.1. Company/organisation
Provide the name and address of the company or organisation.18
1.2.2. Contact person
Indicate the contact person authorised to communicate with EFSA on behalf of the applicant.19
1.3. Speciﬁcations
Please select one of the options below:
□ Application for a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006
Please specify:
□ Based on newly developed scientiﬁc evidence and/or
□ Includes a request for the protection of proprietary data
□ Application for a health claim pursuant to Article 14 of Regulation (EC) No 1924/2006
Please specify:
□ Reduction of disease risk claim
□ Claim referring to children’s development and health
□ Application for a modiﬁcation of an existing health claim authorisation in accordance with
Article 19 of Regulation (EC) No 1924/2006
Please specify:
The health claim that has been authorised and for which the modiﬁcation is requested
The Commission Regulation under which the claim has been authorised
The part of the authorisation which should be modiﬁed
1.4. Proprietary data20
State whether the application includes a request for the protection of proprietary data according to
Article 21 of Regulation (EC) No 1924/2006:
□ yes
□ no
18 In case more than one company or organisation submits an application, provide their names and addresses. Only one contact
person is authorised to communicate with EFSA.
19 To facilitate communication, only one contact person should be indicated per application.
20 See also Annex A (section A.4) of the ‘general guidance’ (EFSA NDA Panel, 2016).
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If yes, please specify the Part(s) of the application which include proprietary data for which
protection is requested, clearly stating section(s) and page number(s):
Provide veriﬁable justiﬁcation21/declaration for the proprietary claim:
1.5. Conﬁdential data20
State whether the application includes conﬁdential data
□ yes
□ no
If yes, please specify the Part(s) in the application (including unpublished studies) which contain
conﬁdential data, clearly stating section(s) or data sets, and page number(s), and veriﬁable justiﬁcation
(s)/reasons(s) why the afore-mentioned information needs to be kept conﬁdential should be provided:
Elements of the application dossier for which a
request for conﬁdentiality treatment was ﬁled by
the applicant
Section(s) or data sets,
and page number(s)
Veriﬁable
justiﬁcation(s)/
reasons(s)
1.6. Regulatory status outside the European Union
If this health claim or a similar one has been submitted by the applicant to any regulatory body for
authorisation outside the EU, please indicate the status of the evaluation of such health claim by each
regulatory body (if more than one):
□ Under consideration
Specify the claimed effect, the wording of the claim, the food/constituent for which the claim has
been submitted and the date of submission. Indicate the recipient regulatory body.
□ Withdrawn
Specify the claimed effect, the wording of the claim, the food/constituent for which the claim was
withdrawn, the date of withdrawal and the reason for withdrawal. Indicate the regulatory body at the
time of withdrawal.
□ Approved
Specify the approved claimed effect and the wording of the claim, the food/constituent for which the
claim has been approved, and the date of approval. Indicate the authorising regulatory body, and if
available, provide a copy of the scientiﬁc opinion of the authorising regulatory body (in Part 6, Section 6.2).
□ Rejected
Specify the rejected claimed effect and the wording of the claim, the food/constituent for which the
claim has been rejected, the date of rejection and the reasons for rejection. Indicate the regulatory
body which rejected the health claim, and if available, provide a copy of the scientiﬁc opinion of the
regulatory body which rejected the health claim (in Part 6, Section 6.2).
21 Precise and factual information, ideally documents, proving that disclosure of the information requested by the applicant to be
treated as conﬁdential would result in concrete harm to the commercial or economic interest of the applicant/requestor or
would undermine the protection of privacy and/or integrity of concerned individual(s).
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1.7. Health claim particulars
1.7.1. Specify the food/constituent for which the health claim is made
1.7.2. Describe the relationship between the food/constituent and the claimed
effect, including the outcome variable(s) used to assess the claimed effect
in vivo in humans and the methods of measurement
1.7.3. Provide a proposal for the wording of the health claim
The proposed wording should be in English.
1.7.4. Conditions of use
Specify the target population for the health claim.
Indicate the quantity of the food/constituent and pattern of consumption required to obtain the
claimed effect, and whether this quantity could reasonably be consumed as part of a balanced diet.22
Provide, where appropriate, a statement addressed to the category(ies) of the population who
should avoid using the food/constituent for which the health claim is made, and include a rationale.
Specify, where applicable, a warning for any food/constituent that is likely to present a health risk if
consumed in excess, and provide a rationale.
Specify, where applicable, other restrictions of use, and provide a rationale.
Specify, where applicable, directions for preparation and/or use.
1.8. Application form and summary of the application
Please use the application form provided in Appendix A.
For summary of the application, please use the form provided in Appendix B.
Information requested in Appendices A and B are mandatory.
Supporting documents cited (e.g. the scientiﬁc opinion of other regulatory bodies outside the EU) in
Part 1 should be provided in Part 6 (Section 6.2).
2. Part 2: Characterisation of the food/constituent23
Indicate if the food/constituent that is the subject of the health claim is:
□ a single constituent or a ﬁxed combination of constituents. If yes, please go to Section 2.1, and
where applicable to Sections 2.3 and 2.4.
□ a food or a food category. If yes, please go to Section 2.2, and where applicable to Sections 2.3
and 2.4.
22 For claims based on the essentiality of nutrients, conditions of use are set on the basis that any signiﬁcant amount of the
essential nutrient in the diet will contribute to the claimed effect (e.g. conditions of use can be linked to nutrition claims). See
also sections 6.2 and 7.9 of the ‘general guidance’ (EFSA NDA Panel, 2016).
23 See also section 7.1 of the ‘general guidance’ (EFSA NDA Panel, 2016).
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2.1. Single constituent or ﬁxed combination of constituents
For single constituents or ﬁxed combinations of constituents, which are exclusively vitamins and/or
minerals, please go to Section 2.1.1.
For single constituents which are not vitamins or minerals as described in Section 2.1.1, and for
ﬁxed combinations of constituents in which at least one constituent is NOT a vitamin or a mineral (e.g.
a combination of EPA + DHA + GLA24 at a weight ratio of 9:3:1), please go to Section 2.1.2.
2.1.1. Vitamins and minerals
If the food constituent for which the claim is made is a vitamin or a mineral, or a ﬁxed combination
of vitamins and/or minerals, and its characterisation relates to the chemical form of the nutrient(s)
naturally present in foods and forms that are permitted for addition to foods, please specify:
The name of the food/constituent:
The chemical forms to which the health claim applies (one or more among those included in the
Annexes to Directive 2002/46/EC25 and to Regulation (EC) No 1925/200626):
2.1.2. Food/constituents other than vitamins and minerals falling under
Section 2.1.1
Name, the characteristic(s),27 the source and speciﬁcations (e.g. physical and chemical properties,
composition, and where applicable, microbiological constituents) of the constituent(s), or ﬁxed
combination of constituents, for which the health claim is made should be provided.
The variability from batch to batch should be addressed.
Analytical methods applied should be scientiﬁcally sound and standardised to ensure quality and
consistency of the data.
Measurements should be performed in a competent facility that can certify the data. Whenever a
quality control system is in place for performance/control/documentation (e.g. GLP and applicable ISO
standard) the particular system should be indicated.
2.2. Food or category of food
A brief description of the food or food category, including characterisation of the food matrix and
the overall composition (including the nutrient content of the food), should be provided.
The source and speciﬁcations of the food or food category for which the health claim is made
should be provided, and in particular the content of the food/constituent(s) which may contribute to
exert the claimed effect, if known.
The variability from batch to batch should be addressed.
24 Eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA) + gamma-linolenic acid (GLA).
25 Directive 2002/46/EC of the European Parliament and of the Council of 10 June 2002 on the approximation of the laws of the
Member States relating to food supplements. OJ L 183, 12/7/2002 p. 0051–0057.
26 Regulation (EC) No 1925/2006 of the European Parliament and of the Council of 20 December 2006 on the addition of
vitamins and minerals and of certain other substances to foods. OJ L 404, 30.12.2006, p. 26–38.
27 Information relates to those characteristics which may inﬂuence the speciﬁc physiological effect that is the basis of the claim.
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Analytical methods applied should be scientiﬁcally sound and standardised to ensure quality and
consistency of the data.
Measurements should be performed in a competent facility that can certify the data. Whenever a
quality system is in place for performance/control/documentation (e.g. GLP and applicable ISO
standard) the particular system should be indicated.
2.3. Manufacturing process
Where applicable, a brief overview of manufacturing process, including e.g. information that the
food/constituent can be manufactured consistently to the stated speciﬁcations, should be provided. If
the production follows a quality system (e.g. GMP), the particular system should be indicated.
If the manufacturing process is claimed as conﬁdential, a non-conﬁdential summary of the
manufacturing process should also be provided in the dossier for transparency reasons.
2.4. Stability information
Where applicable, a brief summary of the studies undertaken28 (e.g. conditions, batches and
analytical procedures), and of the results and conclusions of the stability studies, should be provided.
Conclusions with respect to storage conditions and shelf-life should be given.
2.5. References
Provide a complete list of the references quoted in Part 2 (alphabetical order of ﬁrst authors).
Supporting documents should be provided in Part 6 (Section 6.2).
3. Part 3: Characterisation of the claimed effect29
3.1. Function claims
The proposed health claim is based on the essentiality of a nutrient12
□ yes □ no
If yes, please specify:
a) the function of the body that is the subject of the claimed effect.
b) the rationale/reasons why the body function is a beneﬁcial physiological effect for the target
population for which the claim is intended.
If not,30 please specify:
a) the speciﬁc body function that is the subject of the claimed effect.
b) the rationale/reasons why the speciﬁc body function is a beneﬁcial physiological effect for the
target population for which the claim is intended.
28 Stability studies should focus on the food/constituent for which the claim is proposed (i.e. the food/constituent which is
expected to exert the claimed effect). The information provided should ensure consistency and stability of the food/
constituent in the ﬁnal food product as consumed.
29 See also section 7.2 of the ‘general guidance’ (EFSA NDA Panel, 2016).
30 See section 7.2.1 of the ‘general guidance’ (EFSA NDA Panel, 2016).
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c) how the speciﬁc body function can be assessed in vivo31 in humans by generally accepted
methods. Please indicate the outcome variable(s) and the methods of measurement proposed
to assess the claimed effect in human studies.
3.2. Disease risk reduction claims32
3.2.1. Deﬁnition of the claimed effect
Please specify:
a) the risk factor for the development of the human disease:
b) how the speciﬁc risk factor can be assessed in vivo33 in humans. Please indicate the
outcome variable(s) and the methods of measurement proposed to assess the risk factor in
human studies:
c) the disease to which the risk factor relates:
d) the criteria used for the diagnosis of the disease (i.e. the criteria used for diagnosis are
widely accepted by the medical community and can be veriﬁed by a physician):
3.2.2. Characterisation of the relationship between the risk factor and the risk of
the related disease
If available, provide evidence from observational studies for an independent association between
the proposed risk factor and the incidence of the disease:
Provide evidence that the relationship between the risk factor and the development of the disease
is biologically plausible:
If available, provide evidence from intervention (drug or dietary) studies that a reduction of the risk
factor generally reduces the incidence of the disease:
3.3. References
Provide a complete list of the references quoted in Part 3 (alphabetical order of ﬁrst authors):
Full reprints of the references quoted should be provided in Part 6 (Section 6.3).
4. Part 4: Identiﬁcation of pertinent scientiﬁc data
4.1. Claims based on the essentiality of nutrients12
The procedure followed to identify the evidence on the essentiality of the nutrients should be
depicted.
31 It includes the measurement of functional outcome variables in vivo and the measurement (ex vivo) of outcome variables in
biological samples following an intervention in vivo.
32 See also section 7.2.2 of the ‘general guidance’ (EFSA NDA Panel, 2016).
33 It includes the measurement of functional outcome variables in vivo and the measurement (ex vivo) of outcome variables in
biological samples following an intervention in vivo.
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Provide case reports of clinical signs and symptoms of deﬁciency, depletion–repletion studies in
humans, animal studies, in vitro studies, and/or any other evidence (in favour and not in favour) to
establish that:
i) the food/constituent is required for normal human body function(s), i.e. it has an essential
mechanistic role in a metabolic function and/or it has the ability to reverse clinical signs and
symptoms of its deﬁciency;
ii) the food/constituent cannot be synthesised by the body, or cannot be synthesised in
amounts which are adequate to maintain normal human body function(s);
iii) the food/constituent must be obtained from a dietary source (i.e. a source which is
appropriate for human oral consumption).
A complete list of the references (alphabetical order of ﬁrst authors) should be provided and
organised as follows:
a) depletion–repletion studies in humans
b) case reports of clinical signs and symptoms of deﬁciency in humans
c) animal studies
d) in vitro studies
e) review publications (e.g. narrative reviews, text-book chapters, etc.)
Full reprints of references quoted should be provided in Part 6 (Section 6.4).
4.2. Claims other than those based on the essentiality of nutrients
4.2.1. Identiﬁcation of published human studies on the relationship between the
consumption of the food/constituent and the claimed effect34
Published human studies on the relationship between the consumption of the food/constituent and
the claimed effect should be identiﬁed in a systematic and transparent manner through a
comprehensive review of the scientiﬁc literature.35
The following information on the comprehensive review should be provided, as appropriate:
Authorship
Name, afﬁliation, declaration of interests and signature of the reviewer(s) responsible for the
comprehensive review should be indicated.
Objectives
The questions that the comprehensive review aims to address should be clearly speciﬁed in relation
to the study group(s), the food/constituent, the comparator (if applicable), the outcome variable(s)
used to assess the claimed effect, the methods of measurement which are considered valid with
respect to their analytical characteristics, and the study design(s).
Eligibility criteria
Specify the inclusion (and exclusion) criteria applied in order to select publications that are
considered pertinent to the health claim with respect to the study group(s), the food/constituent, the
34 See also section 7.4 of the ‘general guidance’ (EFSA NDA Panel, 2016).
35 Applicants could consider the EFSA guidance on the application of systematic review methodology to food and feed safety
assessments to support decision-making for that purpose (EFSA, 2010).
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comparator (if applicable), the outcome variable(s) used to assess the claimed effect, the methods of
measurement, the study design(s), and other characteristics, where appropriate.
Literature search and other data sources
The databases that have been searched should be listed.
Please provide the full search strategy, including the terms used, limits used (e.g. publication dates,
publication types, languages, population subgroups or default tags), in order to allow replication. Other
sources of data used to retrieve pertinent published human studies should be acknowledged (e.g. web
sites, hand searching, expert knowledge).
Published human studies on the relationship between the consumption of the
food/constituent and the claimed effect identiﬁed as pertinent to the health claim
a) Provide a reference list of the publications that have been identiﬁed through the literature
search (and/or other data sources) and which have been considered as pertinent to the health
claim (i.e. which meet the eligibility criteria speciﬁed above). The reference list should be
organised in accordance with the hierarchy of study design and publication type as follows:
a.1) Publications reporting on human intervention (efﬁcacy) studies (e.g. randomised
controlled studies, randomised uncontrolled studies, non-randomised controlled
studies, other intervention studies)
a.2) Publications reporting on human observational studies (e.g. cohort studies, case–
control studies, cross-sectional studies, other observational studies)
a.3) Summary publications reporting on human intervention and/or human observational
studies (e.g. systematic reviews, pooled analyses, meta-analyses, other review
publications)
Full reprints of the above-mentioned publications should also be provided in Part 6
(Section 6.4).
b) Please provide a reference list of the publications that have been identiﬁed through the
literature search (and/or other data sources) on the relationship between the consumption of
the food/constituent and the claimed effect, which have NOT been considered as pertinent to
the health claim (i.e. which do NOT meet the eligibility criteria speciﬁed above). For each
publication, the reason(s) for exclusion of the publication from the application should be
clearly speciﬁed. The full text of these publications should NOT be provided in the application.
4.2.2. Unpublished human studies on the relationship between the consumption
of the food/constituent and the claimed effect
The procedure followed to identify unpublished human studies that are considered as pertinent to
the health claim should be depicted.
Reference list of unpublished human studies
Provide a reference list of any unpublished human (intervention or observational) studies and of
any summary publication (systematic reviews/meta-analyses/pooled analyses) reporting on human
(intervention or observational) studies which the applicant considers as being pertinent to the health
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claim. The reference list should be organised in accordance with the hierarchy of study design and
publication type, as follows:
a.1) Human intervention (efﬁcacy) studies (e.g. randomised controlled studies, randomised
uncontrolled studies, non-randomised controlled studies, other intervention studies)
a.2) Human observational studies (e.g. cohort studies, case–control studies, cross-sectional
studies, other observational studies)
a.3) Summary reports of human intervention and/or human observational studies (e.g.
systematic reviews, pooled analyses, meta-analyses, other reviews)
The full protocol and the full study report of the above-mentioned studies SHOULD be provided in
Part 6 (Section 6.5).
For study reports of human efﬁcacy studies (unpublished and/or proprietary), please see
Appendix C for the content requirements.
4.2.3. Published and unpublished supportive evidence
The procedure(s) followed to identify published and unpublished studies other than human studies
on the relationship between the consumption of the food/constituent and the claimed effect (e.g.
bioavailability studies, studies on the mechanism(s) by which a food could exert the claimed effect)
should be depicted.
Reference list of published/unpublished studies
Provide a reference list of the publications/unpublished studies other than human studies on the
relationship between the consumption of the food/constituent and the claimed effect which have been
considered as pertinent to the health claim. The reference list should be organised in accordance with
the hierarchy of study design and publication type, as follows:
a) human studies
b) animal efﬁcacy studies
c) other animal studies
d) in vitro studies
Full reprints of the above-mentioned publications, and the full protocol and study report for
unpublished studies, should also be provided in Part 6 (Section 6.4 for published studies and
Section 6.5 for unpublished studies).
5. Part 5: Overall summary of pertinent scientiﬁc data
The scope of this section is to critically and concisely summarise the extent to which the
relationship between the consumption of the food/constituent and the claimed effect is supported by
the totality of the evidence identiﬁed as pertinent to the health claim in Part 4 of the application.
Note: No new/additional references should be cited in Part 5, except those identiﬁed in Part 4.
5.1. Claims based on the essentiality of nutrients12
Provide a reasoned and concise summary on the extent to which:
i) the food/constituent is required for normal human body function(s), i.e. it has an essential
mechanistic role in a metabolic function and/or it has the ability to reverse clinical signs and
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symptoms of its deﬁciency. Please provide a rationale for the relationship between the
metabolic function and/or the speciﬁc clinical signs and symptoms of deﬁciency and the
human body function that is the subject of the health claim.
ii) the food/constituent cannot be synthesised by the body, or cannot be synthesised in
amounts which are adequate to maintain the normal body function that is the subject of the
health claim.
iii) the food/constituent must be obtained from a dietary source (i.e. a source which is
appropriate for human oral consumption).
Cross-references to the pertinent scientiﬁc data identiﬁed in Part 4 (section 4.1) should be given,
where appropriate.
5.2. Claims other than those based on the essentiality of nutrients
The scope of Sections 5.2.1 and 5.2.2 is to critically and concisely summarise the extent to which
the relationship between the consumption of food/constituent and the claimed effect is supported by
the totality of (published and unpublished) human studies identiﬁed as pertinent to the health claim in
Part 4 (Sections 4.2.1 and 4.2.2) of the application. Cross-references to pertinent human studies
(intervention or observational) should be given, as appropriate.
5.2.1. Substantiation of a causal relationship between the consumption of the
food/constituent and the claimed effect
The extent to which the data substantiate a causal relationship between the consumption of the
food/constituent and the claimed effect should be addressed by considering:
i) the speciﬁcity of the effect;
ii) the dose–response relationship;
iii) the magnitude of the effect and its physiological relevance;
iv) the consistency of the effect across studies (consistent results obtained from studies by
different research groups and/or in different settings strengthen the evidence).
5.2.2. Characterisation of the relationship between the consumption of the
food/constituent and the claimed effect
The relationship between the consumption of the food/constituent and the claimed effect should be
characterised by considering:
i) the study group(s) in which the effect has been demonstrated and whether study groups are
representative of the target population;
ii) the conditions under which the effect has been achieved (metabolic room, clinical setting,
free-living subjects, etc.);
iii) the sustainability of the effect over time with continuous consumption of the
food/constituent, where applicable;
iv) the lowest effective dose, when available;
v) the amount of the food/constituent used to achieve the effect, the usual intakes of the
food/constituent in the target population, and whether these amounts could be reasonably
consumed as part of a balanced diet.
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5.2.3. Supportive evidence
Bioavailability
Where applicable, concisely summarise the relevant data and rationale to support that the food/
constituent for which the health claim is made is in a form that is available to be used by the human
body.
If available, describe any factors (e.g. formulation and processing) that could affect the absorption
or utilisation in the body of the food/constituent for which the health claim is made.
Note: If absorption is not necessary to produce the claimed effect (e.g. plant sterols, ﬁbres and
lactic acid bacteria), concisely summarise the relevant data and rationale to support that the food/
constituent reaches the target site.
Mechanism(s) of action
If known, concisely describe the mechanism(s) by which the food/constituent could exert the
claimed effect. If the food/constituent is a ﬁxed combination of constituents, please indicate how each
constituent could contribute to the claimed effect.
Cross-references to published and unpublished supportive studies identiﬁed in Part 4 (Section 4.2.3)
should be given, as appropriate.
Summary of supportive evidence
This section should critically and concisely summarise how, and the extent to which, the published
and unpublished studies other than human studies on the relationship between the consumption of the
food/constituent and the claimed effect identiﬁed in Part 4 (Section 4.2.3) may help to support the
relationship between the food/constituent and the claimed effect in humans (e.g. by providing
evidence on the biological plausibility of the speciﬁc claim, including bioavailability of the
food/constituent, and the mechanisms by which the food/constituent could exert the claimed effect).
6. Part 6: Annexes to the application
6.1. Glossary and abbreviations
Used throughout the different Parts. To be presented alphabetically.
6.2. Supporting documents and copies/reprints of references cited in
Parts 1 and 2
Supporting documents referred to in Part 1. If available, include here, e.g. scientiﬁc opinions of
regulatory bodies outside the EU for health claim authorisation:
Supporting documents referred to in Part 2 related to characterisation of the food/constituent.
Copies/reprints should be provided by alphabetical order of ﬁrst authors.
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6.3. Copies/reprints of references related to characterisation of the
claimed effect cited in Part 3
Copies/reprints should be provided by alphabetical order of ﬁrst authors.
6.4. Copies/reprints of pertinent published data identiﬁed in Part 4
Copies/reprints of pertinent published data identiﬁed in Part 4 (Sections 4.1, 4.2.1 and 4.2.3)
should be provided by alphabetical order of ﬁrst authors.
6.5. Full study protocols and reports of pertinent unpublished data
identiﬁed in Part 4
Copies/reprints of pertinent unpublished data identiﬁed in Part 4 (Sections 4.2.2 and 4.2.3) should
be provided by alphabetical order of ﬁrst authors.
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Glossary and Abbreviations
Notes: The deﬁnitions given in this glossary are valid only for the purpose of this guidance document
Applicant Refers to the natural or legal person responsible for the submission and
content of the application and for the interaction with regulatory authorities
in the course of the evaluation until such time as the claim is included in the
lists of permitted or rejected health claims by Commission Decision.
Application Means a stand-alone dossier containing the information and scientiﬁc data
submitted for authorisation of the health claim in question
Central laboratory In a multicentre study, a laboratory is termed to be a central laboratory, if all
samples for a certain analysis are sent to a single (central) laboratory for
analysis
Clinical study
with adaptive design
A study with a prospectively planned opportunity for modiﬁcation of one or
more speciﬁed aspects of the study design (e.g. sample-size, randomisation
ratio, number of treatment arms) based on an interim analysis with full
control of the type I error (FDA, EMA)
Disease/disorder A pathological process, acute or chronic, inherited or acquired, of known or
unknown origin, having a characteristic set of signs and symptoms which are
used for its diagnosis
Efﬁcacy study An intervention study (in humans, in animals) which investigates the
relationship between the food/constituent and the claimed effect
FAS full analysis set
Health claim Any claim which states, suggests or implies that a relationship exists
between a food category, a food or one of its constituents and health (as
deﬁned in Regulation (EC) No 1924/2006)
ITT Intention-to-treat
Fixed combination
of constituents
Two or more nutrients and/or other substances which are all required in
order to obtain the claimed effect, ideally in speciﬁed amounts
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Food/constituent A food category, a food, or its constituents (including a nutrient or other
substance, or a ﬁxed combination of constituents)
GCP good clinical practice
GLP good laboratory practice
GMP good manufacturing practice
NDA EFSA Panel on Dietetic Products, Nutrition and Allergies
Nutrient Means protein, carbohydrate, fat, ﬁbre, sodium, vitamins and minerals listed
in point 1 of Part A of Annex XIII to Regulation (EU) No 1169/201136, and
substances which belong to or are components of one of those categories
Other substance Without prejudice to Regulation (EC) No 178/200237, it means a substance
other than a nutrient that has a nutritional or physiological effect (as deﬁned
in Regulation (EC) No 1924/2006)
Pertinent study A study from which scientiﬁc conclusions that are relevant to the
substantiation of a claim (e.g. efﬁcacy studies, bioavailability studies, studies
on the mechanism(s) by which a food could exert the claimed effect) can be
drawn
PP per-protocol
Study group Individuals recruited for human studies which are submitted for the scientiﬁc
substantiation of a claim
Suitable study group A study group which is representative of the target population for the claim
or a study group from which extrapolation of the results to the target
population is biologically appropriate
Supportive evidence Studies/data which, on their own, are not sufﬁcient for the scientiﬁc
substantiation of a claim and that may be part of the totality of the evidence
only if pertinent human studies showing an effect of the food/constituent are
available
Target population The population group(s) for which health claims are intended (e.g. the
general healthy population or speciﬁc subgroup(s) thereof)
Totality of the evidence All the studies (e.g. in humans, in animals, in vitro) which are taken into
consideration to conclude on the substantiation of a claim (including studies
in favour and not in favour of the claim)
36 Regulation (EU) No 1169/2011 of the European Parliament and of the Council of 25 October 2011 on the provision of food
information to consumers, amending Regulations (EC) No 1924/2006 and (EC) No 1925/2006 of the European Parliament and
of the Council, and repealing Commission Directive 87/250/EEC, Council Directive 90/496/EEC, Commission Directive 1999/10/
EC, Directive 2000/13/EC of the European Parliament and of the Council, Commission Directives 2002/67/EC and 2008/5/EC
and Commission Regulation (EC) No 608/2004. J L 304, 22.11.2011, p. 18–63. http://eur-lex.europa.eu/legal-content/EN/TXT/
PDF/?uri=CELEX:32011R1169&from=EN
37 Regulation (EC) No 178/2002 of the European Parliament and of the Council of 28 January 2002 laying down the general
principles and requirements of food law, establishing the European Food Safety Authority and laying down procedures in
matters of food safety. Ofﬁcial Journal of the European Union OJ L 31, 1.2.2002, p. 1–24.
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Appendix A – Application form [Mandatory]
Application form
The application form should be used for an application for a health claim pursuant to Article 13(5)
or 14, or for a modiﬁcation of an existing authorisation in accordance with Article 19 of Regulation
(EC) No 1924/20061 submitted to a Member State of the European Union for the scientiﬁc evaluation
by the European Food Safety Authority (EFSA).
A separate application form for each health claim is required.
Food/constituent38 (specify as appropriate):
Proposed wording of the health claim:
Application for a health claim pursuant to:
□ Article 13(5) of the Regulation 1924/2006
□ Article 14 of Regulation 1924/2006 – Claim referring to children’s development and health
□ Article 14 of Regulation 1924/2006 – Reduction of disease risk claim
□ Article 19 of Regulation (EC) No 1924/2006 – for a modiﬁcation of an existing authorisation
Specify the recipient Member State’s Competent Authority:
Applicant39:
(Company) Name:
Address:
Country:
Contact person19:
Name:
Company name:
Address:
Country:
Telephone/mobile number:
E-Mail:
It is hereby conﬁrmed to our best knowledge that all existing data which are relevant to the health
claim authorisation have been supplied in the application, as appropriate.
On behalf of the applicant:
Signature
Name
Function
Place and date (dd-mm-yyyy)
38 ‘Food/constituent’ refers to a food category, a food or its constituents (including a nutrient or other substance, or a fixed
combination of constituents).
39 In case more than one company or organisation submit an application, provide their names and addresses.
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Appendix B – Summary of the application [Mandatory]
Summary of the application
The template provided should be used for the summary of the application for a health claim
pursuant to Article 13(5) or 14, or for a modiﬁcation of an existing authorisation in accordance with
Article 19 of Regulation (EC) No 1924/20061 submitted to a Member State of the European Union for
the scientiﬁc evaluation by the European Food Safety Authority (EFSA).
Note: The summary of the application should not contain conﬁdential data. For claims falling under
the scope of Article 14, EFSA will make public the summary of the application as provided by the
applicant.
General information
Applicant39:
(Company) Name:
Address:
Country:
Recipient Member State of Application:
This application concerns:
□ a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006
□ a health claim referring to disease risk reduction pursuant to Article 14 of Regulation (EC)
No 1924/2006
□ a health claim referring to children’s development and health pursuant to Article 14 of
Regulation (EC) No 1924/2006
□ a modiﬁcation of an existing health claim authorisation in accordance with Article 19 of
Regulation (EC) No 1924/2006
Please specify:
□ Modiﬁcation of an authorised Article 14 health claim
□ Modiﬁcation of an authorised Article 13(5) health claim
Health claim particulars
Specify the food/constituent:
Describe the relationship between the food/constituent and the claimed effect, including the outcome
variable(s) used to assess the claimed effect in vivo in humans and the methods of measurement:
Proposal for the wording of the health claim:
Specify the conditions of use:
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Appendix C – Information to be presented in a full study report for human
efﬁcacy studies (unpublished and/or proprietary)
A study report can be considered complete when it contains at least the information outlined in this
Appendix. This Appendix has been adapted from the International Conference on Harmonisation (ICH)
guideline E3 on the structure and content of clinical study reports40 for the purpose of health claim
substantiation. Study reports which follow the full structure of ICH E3 are also acceptable.
Study reports not complying with the requirements outlined below may not allow a scientiﬁc
evaluation of the study by the NDA Panel.
1) Title page
The title page should include information on the food/constituent under investigation, the primary
outcome variable(s) studied, the method(s) of measurement used to assess the outcome variable(s)
in vivo in human, the study design (e.g. double or single-blind, two or more arms/periods, parallel or
cross-over, single or multicentre), the study group(s), the study initiation and completion date, the
place in which the study was conducted, the name of the sponsor, the funding source and its exact
role and contribution to the study (e.g. in the design, conduct, analysis and/or reporting of the study,
if any), the name of the principal investigator, the name of the author of the report and the date when
the report has been signed off.
2) Summary
3) Table of contents
4) List of abbreviations and deﬁnition of terms
5) Ethical considerations
This should include information about the review and approval of the study by an ethics committee.
Information about the ethical conduct of the study, about how the informed consent was obtained
from participants should be provided. If a review or approval by an ethics committee was not
provided, this should be speciﬁed and duly justiﬁed.
6) Trial registration
It should be speciﬁed whether the study has been registered in a trial registry. If so, the trial
registration number should be given. In case the study has not been registered, explanation should be
given.
7) General information about the study
In this section, the name/afﬁliation of the investigators and other people with a major role in the
study (e.g. staff carrying out observations related to the outcome variable(s) under investigation), the
statisticians and the authors of the report, should be provided. The section should also include
information about the facilities which were used (e.g. for multicentre studies: information about the
study sites and about the use of a central laboratory vs non-central sample analyses), and on whether
a contract research organisation has been tasked to carry out the work.
8) Study objectives
The objective(s) of the study and the hypothesis to be tested should be speciﬁed in this section.
9) Study design
This section should outline whether the study was planned, e.g. as open-label, single-blind
(specifying who was blinded) or double-blind study, as a single- or multicentre study (with a
speciﬁcation about the number of study sites). Information about the country setting, the type of
control used (and the reasons why it was considered appropriate in the context of the study), the
study duration and a discussion on the choice of the study design for investigating the selected
outcome variable(s) should also be provided. In case the study was planned with an adaptive design,
it should be speciﬁed which kind of adaptations at which time points were planned in the protocol and
whether a Data Monitoring Committee was involved in the implementation of the plan.
40 http://www.ich.org/products/guidelines/efficacy/article/efficacy-guidelines.html
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10) Study group
The inclusion and exclusion criteria should be described, including the diagnostic criteria (and their
validation) used to select subjects, if applicable. The appropriateness of the study group for the
particular purpose of the study should be discussed. Any predeﬁned criteria for excluding subjects
from the study after randomisation should also be given, together with information on how these
subjects were intended to be followed up.
11) Study products
A detailed description of the food/constituent41 under investigation and the control used (if any),
including information on the mode of administration, and the amounts used, should be provided.
12) Method of assigning subjects to groups
Details on the method used to assign subjects to the study groups (randomisation or minimisation)
should be given. It should be speciﬁed whether this allocation was done in a centralised or
decentralised way, whether it was stratiﬁed (and if so by which factors) or whether the allocation was
done in blocks. Information on the measures taken to conceal the allocation should also be described
here.
13) Blinding
Information on the strategy used to ensure blinding should be provided, e.g. measures taken to
achieve that the study products were not distinguishable by smell, taste, colour, shape or packaging;
how products were labelled (e.g. by subject individual codes or other). Information should be given on
who had access to the product codes, whether there were any predeﬁned circumstances in which the
blinding could be broken and who from the team of investigators would be unblinded in case of such a
need. If proper blinding could not be achieved, please discuss and justify why this was not possible.
For studies with an adaptive design, it should be reported how it was ensured that the study personnel
remained blinded to the interventions, especially if the preplanned adaptation required unblinding of
the data. In such a case, it should be justiﬁed why the particular adaptation made it necessary to
unblind the data and why the same aim could not have been achieved with statistical methods not
requiring such unblinding.
14) Concomitant medication or interventions
Any concomitant medication or non-pharmacological interventions, any rescue medication allowed
by the study protocol should be described here (e.g. name of medication, dose and posology, type of
non-pharmacological intervention, frequency, duration).
15) Compliance with the intervention and the protocol
This section should include a detailed description about the measures taken to ensure and assess
compliance with the intervention and the protocol.
16) Outcome variable(s) measured
Information about the predeﬁned primary outcome variable(s), secondary outcome variable(s) and
all other outcomes planned to be measured should be presented in this section.
The methods used to assess the outcome variable(s) should be speciﬁed.
This section should also include information about the timing of the measurements (e.g. ﬂow
chart), and a justiﬁcation of the appropriateness of the outcome variable(s) chosen to achieve the
objective(s) of the study.
17) Data quality assurance
Any measures taken with respect to the quality assurance and quality control systems implemented
for data collection should be addressed here. Whenever a quality control system has been used/
reported in the conduct of the studies (e.g. GCP, as relevant), the particular system should be
indicated.
41 Sufﬁcient information should be provided to establish that the study was performed with a food/constituent which complies
with the speciﬁcations given for the food/constituent for which the claim is proposed (e.g. the microbial strain(s) used).
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18) Preplanned statistical analyses
This section refers to the statistical analysis planned before the implementation of the study, and
should specify whether any subgroup analyses were preplanned (e.g. whether there was a priori
hypothesis of a differential effect in a particular subgroup of subjects). The choice of each statistical
technique should be appropriately justiﬁed. The data analysis sets (e.g. ITT, FAS, PP) should also be
deﬁned. It should be speciﬁed which of the analyses presented have been prespeciﬁed as the main
analysis in case several alternative analyses for one outcome variable are planned (e.g. ITT vs PP or
different models used). The reasons for the choice of the analysis should be given. If imputation of
missing data is foreseen, information should be given on how it is planned to assess the robustness of
the assumptions made with respect to the imputation of data. For studies for which an adjustment for
multiple comparisons is needed in order to preserve the family-wise type I error rate, the preplanned
approach towards adjusting for multiplicity should be speciﬁed. In case of studies with an adaptive
design, the number and time points of prespeciﬁed interim analyses, as well as the statistical methods
used to conserve the type I error rate, should be given. The appropriateness of the statistical method
used for the design of the study should be discussed. Finally, it should be stated which analyses were
planned to be conﬁrmatory and which ones exploratory.
19) Determination of sample size
Detailed information on how the planned sample size of the study was calculated should be given
here. This should include information about the expected size of the effect, the assumed standard
deviation of the population, the signiﬁcance level chosen, the anticipated power of the study, and the
statistical tests (to be performed) to which the sample size calculation relates. In addition, information
should be given on whether equal or unequal allocation to groups has been accounted for in the
sample size calculation (if unequal allocation is foreseen) and whether any allowance for drop-out has
been made. Finally, the programme used to calculate the sample size should be identiﬁed. In case of
studies with adaptive design allowing for sample size re-estimation, the planned method for re-
estimating sample size should be described.
20) Protocol amendments, deviations and violations/deviations from the planned
approaches and analyses
Non-adherence or changes made during or after the study with respect to the preplanned
approaches or preplanned analyses should be speciﬁed here.
Any protocol amendments (i.e. a systematic change in the protocol after approval), protocol
deviations and violations (i.e. unplanned unsystematic deviations from the protocol with either minor
effects (deviations) or affecting the scientiﬁc integrity (violations)) should be outlined.
A protocol amendment may, for example, relate to a systematic change of the pre-established
inclusion and exclusion criteria, the planned study design, addition or deletion of outcome variable(s),
sample size, the planned statistical approaches or the deﬁnition of data analysis sets (e.g. ITT vs PP).
If no protocol amendments have been made, it should be conﬁrmed that the study was carried out
according to the protocol.
Protocol deviations and violations may relate, for example, to inadequate or not-timely collected
informed consent, inclusion of subjects not meeting the eligibility criteria, improper breaking of the
blind, improper assessment of an outcome variable, incorrect or missing tests, rescheduled or missed
study visits, visits outside the permitted window, inadequate record keeping, use of not permitted
medication or a non-pharmacological intervention.
Any additional exploratory analyses conducted which were not part of the (amended) protocol (e.g.
unplanned subgroup analyses to inform a subsequent study) should also be recorded.
21) Subject ﬂow
A clear description of the number of subjects screened, the number of subjects recruited, the
number of subjects randomised, the number of subjects who entered and completed each study
phase, the number of drop-outs and the number of withdrawals should be speciﬁed. The reasons for
subjects dropping-out of the study or for having been withdrawn from the study by the investigators
should be stated. Information about whether and when the blind was broken (if so) should also be
given here.
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22) Data sets analysed
This section should include a clear deﬁnition of each analysis set used for ﬁnal analysis (e.g. ITT,
FAS, PP), including information on the number of subjects available for each analysis at each
assessment time point. In case PP analyses are presented, information should be given on the extent
to which the subjects included in this analysis set could have deviated from the protocol, and the
reasons why they were still eligible for inclusion in the PP analysis set. Finally, the reasons for
excluding subjects from each analysis at each time point should be given.
23) Baseline characteristics of the study population
In this section, baseline characteristics for all analysis sets should be given (e.g. ITT, FAS, PP,
completers, other) – overall and by study centre for multicentre studies.
24) Results of assessment of compliance with the intervention and the protocol
Results of the assessment of compliance with the intervention and with the protocol should be
given here.
25) Statistical analysis carried out
A detailed description of the statistical analysis carried out should be provided, in line with EFSA’s
guidance on statistical reporting42 (EFSA, 2014). This description should include, among other,
information on:
• the statistical programme used (version number and operating system);
• the type of statistical tests/models used;
• the test/model selection;
• the appropriateness of the test/model used for the type of data generated;
• the handling of missing data (including a detailed description of the potential missingness
mechanism and of how the missing data were handled). If missing data was imputed, please
describe the methods used to do so and specify which sensitivity analyses were carried out, if
any;
• the variables or factors used as ﬁxed or as random effects (if appropriate);
• the assumed covariance structure for longitudinal analyses;
• the adjustment for covariates (and justiﬁcation about the covariates used);
• the handling of data stemming from multicentre trials;
• whether any issue with respect to multiple comparisons arises (in case of multiple primary
outcome variables or multiple group comparisons, or if a secondary outcome variable is
intended to be used as the primary efﬁcacy criterion instead of the primary outcome variable);
this should include a description of the method chosen for adjusting the analysis for multiple
comparisons and information on the number of outcome variables for which the analysis has
been adjusted.
26) Results of the study
Results for all the outcome variables assessed and for all analysis sets investigated should be
presented. The results should be given as estimates with associated conﬁdence intervals and p-values
(if corrected for multiple comparisons, both the uncorrected and the corrected results (conﬁdence
intervals and p-values accounting for multiple comparisons)) should be given. Results should be
presented for all groups under investigation and for each assessment time point if foreseen in the
prespeciﬁed analysis plan; otherwise descriptive statistics should be included. The information should
be presented in a tabular format, and not only graphically. For multicentre trials, results or descriptive
statistics for the individual centres should be presented (if prespeciﬁed). The number of subjects
included in each analysis and assessment time point should be provided. In case of data imputation,
the results of the related sensitivity analyses should be included. The full outputs of the statistical
analyses, together with the associated codes used for programming should be given as an Annex. A
full list of the abbreviations used to denominate variables or factors in the programming should also be
given, so that the statistical outputs are self-explanatory.
42 http://www.efsa.europa.eu/sites/default/files/scientific_output/files/main_documents/3908.pdf
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27) Adverse events
In case adverse events are assessed in the study, adverse events should be clearly reported
(possibly indicating those which may be related to the intervention and those which may be not
related to the intervention), together with information on the (diagnostic) criteria used to ascertain
them.43
43 For reporting of safety-related data see also ICH-E3-‘Structure and contend of study reports’.
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